Vir­tu­al phys­i­cal ther­a­py start­up Hinge Health files to go pub­lic

2 months ago
Health Tech

New Flag­ship start­up aims to trail­blaze ‘AI sci­ence fac­to­ries’

2 months ago
Startups
AI

BioN­Tech's shares dip af­ter post­ing luke­warm rev­enue guid­ance

2 months ago
Pharma

Com­pounders’ mo­tion for pre­lim­i­nary in­junc­tion de­nied in case over tirzepatide short­age

2 months ago
Pharma
Law

Emer­gent sells once-trou­bled man­u­fac­tur­ing site to In­di­an CD­MO

2 months ago
Pharma
Manufacturing

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

2 months ago
R&D
Cell/Gene Tx

#AAD25: What you need to know from Am­gen, Bris­tol My­ers, J&J and more

2 months ago
R&D
Pharma

Ex­clu­sive: FDA blocks drug and de­vice re­view­ers from tak­ing HH­S' buy­out of­fer

2 months ago
R&D

Mired in low ex­pec­ta­tions, No­vo braces for up­com­ing Ca­griSe­ma head-to-head tri­al

2 months ago
R&D

J&J, Pro­tag­o­nist out­line first IBD win for oral IL-23 with $5B+ sales po­ten­tial

2 months ago
R&D

Tre­vi’s mid-stage chron­ic cough da­ta meet ‘home run’ sce­nario, stock soars

2 months ago
R&D

Ar­row­head re­veals small batch of open-la­bel da­ta for 'non-core' kid­ney drug

2 months ago
R&D

No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al

2 months ago
R&D

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

2 months ago
Deals
Pharma

Min­eralys’ Phase 3 blood pres­sure pill da­ta sup­port po­ten­tial FDA ap­proval

2 months ago
R&D
Pharma

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

2 months ago
Deals
AI

FDA and NIH nom­i­nees sail through Sen­ate hear­ings; Tar­iffs’ ear­ly im­pact on drug man­u­fac­tur­ing; Ab­b­Vie’s move ...

2 months ago
Weekly

Start of 2025 comes with gener­ic drug price de­creas­es, sev­er­al ma­jor in­creas­es, re­port finds

2 months ago
Pharma

FDA ap­proves Neu­rotech cell ther­a­py to slow a rare de­gen­er­a­tive eye dis­ease 

2 months ago
Pharma
FDA+

Bay­er eyes cap­i­tal raise as it grap­ples with Mon­san­to cas­es

2 months ago
Pharma
Law

How blue­bird's buy­out of­fer went from $100M up­front to $29M

2 months ago
Deals
Cell/Gene Tx

What the FDA, NIH hear­ings tell us about drug and health pol­i­cy un­der Trump

2 months ago
FDA+

At $300M Kardi­gan start­up, for­mer MyoKar­dia team un­veils its first drug, and it comes from Io­n­is

2 months ago
Startups
Deals

Jeb Keiper steps down from Nim­bus CEO post, busi­ness chief to take over

2 months ago
People
First page Previous page 31323334353637 Next page Last page
A service from the Financial Times